JP2021508672A5 - - Google Patents

Download PDF

Info

Publication number
JP2021508672A5
JP2021508672A5 JP2020519016A JP2020519016A JP2021508672A5 JP 2021508672 A5 JP2021508672 A5 JP 2021508672A5 JP 2020519016 A JP2020519016 A JP 2020519016A JP 2020519016 A JP2020519016 A JP 2020519016A JP 2021508672 A5 JP2021508672 A5 JP 2021508672A5
Authority
JP
Japan
Prior art keywords
syn
peptide immunogen
lys
epitope
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020519016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021508672A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037938 external-priority patent/WO2018232369A1/en
Publication of JP2021508672A publication Critical patent/JP2021508672A/ja
Publication of JP2021508672A5 publication Critical patent/JP2021508672A5/ja
Priority to JP2023040466A priority Critical patent/JP7732676B2/ja
Priority to JP2025032073A priority patent/JP2025090637A/ja
Pending legal-status Critical Current

Links

JP2020519016A 2017-06-16 2018-06-15 シヌクレイノパチーの治療のためのアルファ−シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤 Pending JP2021508672A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023040466A JP7732676B2 (ja) 2017-06-16 2023-03-15 シヌクレイノパチーの治療のためのアルファ-シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤
JP2025032073A JP2025090637A (ja) 2017-06-16 2025-02-28 シヌクレイノパチーの治療のためのアルファ-シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762521287P 2017-06-16 2017-06-16
US62/521,287 2017-06-16
PCT/US2018/037938 WO2018232369A1 (en) 2017-06-16 2018-06-15 Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023040466A Division JP7732676B2 (ja) 2017-06-16 2023-03-15 シヌクレイノパチーの治療のためのアルファ-シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤

Publications (2)

Publication Number Publication Date
JP2021508672A JP2021508672A (ja) 2021-03-11
JP2021508672A5 true JP2021508672A5 (https=) 2021-07-26

Family

ID=64659951

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020519016A Pending JP2021508672A (ja) 2017-06-16 2018-06-15 シヌクレイノパチーの治療のためのアルファ−シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤
JP2023040466A Active JP7732676B2 (ja) 2017-06-16 2023-03-15 シヌクレイノパチーの治療のためのアルファ-シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤
JP2025032073A Pending JP2025090637A (ja) 2017-06-16 2025-02-28 シヌクレイノパチーの治療のためのアルファ-シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023040466A Active JP7732676B2 (ja) 2017-06-16 2023-03-15 シヌクレイノパチーの治療のためのアルファ-シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤
JP2025032073A Pending JP2025090637A (ja) 2017-06-16 2025-02-28 シヌクレイノパチーの治療のためのアルファ-シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤

Country Status (10)

Country Link
US (1) US20210138049A1 (https=)
EP (1) EP3638298A4 (https=)
JP (3) JP2021508672A (https=)
KR (2) KR20200054938A (https=)
AU (2) AU2018283510B8 (https=)
BR (1) BR112019026707A2 (https=)
CA (1) CA3067231A1 (https=)
MX (1) MX2019015286A (https=)
SG (1) SG11201912195TA (https=)
WO (1) WO2018232369A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
CA3079236A1 (en) 2017-10-27 2019-05-02 United Neuroscience Tau peptide immunogen constructs
BR112021012668A2 (pt) 2018-12-28 2021-12-28 United Biomedical Inc Imunógenos de peptídeos que possuem como alvo interleucina 6 (il-6) e formulações dos mesmos para imunoterapia de doenças impactadas pela desregulação de il-6
WO2021236809A2 (en) 2020-05-19 2021-11-25 Othair Prothena Limited Multi-epitope vaccine for the treatment of alzheimer's disease
JP2023536497A (ja) * 2020-08-04 2023-08-25 エイシー イミューン ソシエテ アノニム 免疫原性化合物
JP2023541671A (ja) * 2020-09-17 2023-10-03 プロシーナ バイオサイエンシーズ リミテッド シヌクレイノパチーの処置のためのアルファ-シヌクレインワクチン
KR102505164B1 (ko) * 2020-09-29 2023-02-28 서울대학교산학협력단 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물
EP4357354A1 (en) 2021-06-18 2024-04-24 Sumitomo Pharma Co., Ltd. Epitope peptide of human alpha-synuclein and pharmaceutical composition including said peptide
EP4395894A4 (en) * 2021-09-01 2025-08-06 Vaxxinity Inc METHODS FOR THE PREVENTION AND TREATMENT OF SYNUCLEINOPATHIES
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ-グルカン若しくはマンナンからなるか、又はこれを含む結合体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US20120142902A1 (en) * 2007-02-23 2012-06-07 The Regents Of The University Of California Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
AU2009328505B2 (en) * 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
US12156912B2 (en) * 2012-05-18 2024-12-03 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
CA2885924C (en) * 2012-08-21 2022-12-13 Institute For Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US20170184612A1 (en) * 2014-04-09 2017-06-29 The Trustees Of Columbia University In The City Of New York Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder
WO2015179867A1 (en) * 2014-05-23 2015-11-26 University Of South Florida Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinson's disease

Similar Documents

Publication Publication Date Title
JP2021508672A5 (https=)
JP2006504653A5 (https=)
Rubio et al. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20–38) peptide displayed on bacterial thioredoxin
JP6620386B2 (ja) 産卵低下症候群(eds)予防ワクチン
JP2003529319A (ja) HIV−1gp41を標的化する広範に中和する抗体を誘発する方法
JP2010512792A5 (https=)
JP2008529558A5 (https=)
RU2015142996A (ru) Пептидная вакцина для предупреждения и иммунотерапии деменции альцгеймеровского типа
WO2014031697A2 (en) COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND α-SYNUCLEIN
JP2006516639A5 (https=)
KR20190056382A (ko) 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
JPH05262667A (ja) ウイルス抗原を用いるワクチン
CN107080833A (zh) 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp)
EA022788B1 (ru) Новые терапевтические и диагностические средства
AU2003239401A1 (en) Vaccine adjuvant based on a CD40 ligand
WO2003063899A2 (en) Vaccine adjuvant based on a cd4 0 ligand
TWI507413B (zh) 脂質化多抗原表位疫苗
Li et al. Surface display of classical swine fever virus E2 glycoprotein on gram-positive enhancer matrix (GEM) particles via the SpyTag/SpyCatcher system
TW202334198A (zh) 用於避免感染與治療遠程新冠肺炎之針對SARS-CoV-2 OMICRON BA.4/BA.5的疫苗組成物
WO2021253172A1 (zh) 利用受体识别域诱导抗新冠病毒中和抗体的方法
CN102180971A (zh) 重组β淀粉样肽B细胞表位多肽嵌合抗原、其制备方法和应用
JP2010535504A5 (https=)
CN105949321A (zh) 传染性支气管炎病毒分离株s1蛋白的b细胞抗原表位多肽及其疫苗
CN114773457B (zh) 表达猪源性抗猪流行性腹泻病毒n蛋白单链抗体的重组腺病毒及其构建和用途
JP2022511995A5 (https=)